CYDY - CytoDyn's Future Is Looking Brighter And Brighter: Entering A Transformational Year 2020
Editor's note: Seeking Alpha is proud to welcome Jannik Reiners as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more »
Introduction
Recently, shares of CytoDyn Inc. (OTCQB:CYDY) have rallied more than 300% on huge volume after the company announced a $87.5m licensing deal with privately-held Vyera Pharmaceuticals for their drug candidate leronlimab, a best-in-class CCR5 antagonist, for HIV in the US.
Since then, the company has aroused